Novel tlr4 antagonists

A sequence and receptor technology, applied in the field of novel TLR4 antagonists

Active Publication Date: 2021-08-20
GENESEN CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the necessity of research related to new antagonists that can effectively block the TLR4 signaling pathway and can treat related diseases is still highlighted

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel tlr4 antagonists
  • Novel tlr4 antagonists
  • Novel tlr4 antagonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Example 1: Screening TLR4 / myeloid differentiation protein 2-specific peptides, in order to screen peptides that specifically bind to the TLR4 / myeloid differentiation protein 2 complex, fUSE55 was constructed as a 15-mer peptide, and pHEN2 was constructed as a 12-mer peptide The expression library was phage displayed and a phage display method was performed.

Embodiment 1-1

[0059] Example 1-1: Preparation of expression library

[0060] First, to prepare a 15-mer peptide expression library, use forward primer 5'-TTG ATC GCA AGG ATC GGCTAG C-3' reverse primer 5'-AA GGC CTT GGT ACC GCT GCC ACC(MNN)15 GCT AGC CGA TCC TTGCGA TCA A-3' and Pfu deoxyribonucleic acid (DNA) polymerase (SolGent, Daejeon, Korea) at 90°C, denatured for 30 seconds; at 55°C, annealed for 30 seconds; at 72°C Next, the process of extending for 60 seconds was repeated 25 times to amplify the deoxyribonucleic acid. After using NheI / KpnI to cut the amplified deoxyribose nucleic acid chain, use T4 deoxyribonucleic acid ligase (New England Biolabs, Inc., Ipswich, MA, USA) ) was ligated into the fUSE55 vector. Transfer 3 DNA expression libraries as electrocompetent E. coli cells (electrocompetent E.coli cells) DH10B strain, and finally prepare 6.6 × 10 7 After cloning, amplify and propagate in E. coli strain TG-1.

[0061] And, by preparing a random 12-mer peptide expression librar...

Embodiment 1-2

[0062] Embodiment 1-2: biological panning (Biopanning)

[0063] Biopanning was performed on a modified Griffin-1 library (Griffin H., MRC, Cambridge, UK, unpublished data). More specifically, Nunc Maxisorp 96-well plate (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA) was used in the coating buffer. MA, USA)) coated the resuspended recombinant human TLR4 / myeloid differentiation protein 2 complex (R&D Systems, Inc., Minneapolis, MN, USA) and refrigerated overnight. Then, under normal temperature conditions, after blocking with 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS), under normal temperature conditions, the above-mentioned wells that were refrigerated were exposed to the phage expression library, thereby containing The concentration of bovine serum albumin in phosphate buffered saline (PBST) of Tween 20 (Tween 20) at a final concentration of 0.05% was 1%. The phage bound to the expression library was isolated with 100 μl of elution buffer ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a peptide for inhibiting a TLR4 signal transmission pathway, a TLR4 antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. In more detail, peptides that bind to TLR4 / MD2 complexes to inhibit the secretion of interleukin-6 (IL-6), NO and ROS, and the activation of NFκB and MAPKs, TLR4 antagonists containing the above peptides, autoimmune diseases And a composition for the prevention or treatment of inflammatory diseases. The peptide of the present invention has an excellent effect of inhibiting the secretion of interleukin-6 (IL-6), NO and ROS and the activation of NFκB and MAPKs by inhibiting the TLR4 signal transmission pathway induced by lipopolysaccharide (LPS). The composition for preventing or treating autoimmune diseases and inflammatory diseases in which the TLR4 signal transmission pathway occurs is effectively utilized.

Description

technical field [0001] The present invention relates to a peptide for inhibiting TOLL-like receptor 4 signaling pathway, a TOLL-like receptor 4 (TLR4) antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. More specifically involved in binding to the TOLL-like receptor 4 / myeloid differentiation protein 2 (MD2) complex to inhibit the secretion of interleukin-6 (IL-6), NO, and reactive oxygen species (ROS) and nuclear factor activation of B cells A kappa light chain enhancer and mitogen-activated protein kinase (MAPKs) activating peptide, a TOLL-like receptor 4 antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. Background technique [0002] As innate immunity in the immune system of mammals as the first defense against bacterial infection recognition of pattern recognition receptors such as Toll-like receptors (TLRs; Toll-like rece...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/08C07K14/47
CPCC07K7/08C07K14/47A61K38/00A61P37/00A61P29/00C07K14/4703C07K16/2896
Inventor 崔相敦俞兑炫朴雪喜
Owner GENESEN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap